A randomized, open, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single dosing of each enteric-coated geomatrix control release tablet strength (12.5, 25, 37.5mg) in healthy Chinese subjects
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Paroxetine (Primary)
- Indications Depressive disorders; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 20 Apr 2008 Status changed from in progress to completed.
- 07 Dec 2006 New trial record.